Screening for ovarian cancer

Clin Obstet Gynecol. 2006 Sep;49(3):433-47. doi: 10.1097/00003081-200609000-00004.


The efficacy of ovarian cancer screening remains to be proven. Advances in ultrasound and tumor marker technology, combined with complex statistical analysis have facilitated 2 large ongoing randomized controlled trials of screening which are powered to determine the impact on mortality. Serum proteomics seems to be a promising area for biomarker discovery, but requires more rigorous validation before it can be used in clinical trials. Current screening tests, clinical trials in the general and high-risk populations, screening acceptability and costs are reviewed in this article.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / analysis
  • Female
  • Humans
  • Mass Screening / economics
  • Mass Screening / methods*
  • Ovarian Neoplasms / diagnosis*
  • Ovarian Neoplasms / epidemiology
  • Physical Examination
  • Ultrasonography
  • Uterus / diagnostic imaging


  • Biomarkers, Tumor